AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$TNXP

BAGGER RICHARD H purchased $13K of TNXP

BAGGER RICHARD H purchased 1,000 shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $12.60 on 2026-08-20.

Original reporting
SEC EDGAR · BAGGER RICHARD H
Published Aug 24, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TNXP
Neutral
high confidence
Mentioned
$TNXP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNXPNeutralLow
01

Why it matters

The purchase is modest and unlikely to affect TNXP's price.

02

Market read

Minor insider purchase with low trading relevance.

03

What to watch

Potential upcoming clinical data could make this purchase more meaningful.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$TNXPNeutralHigh confidence
Context

Director Richard Bagger purchased 1,000 shares for $12,600 in a Form 4 filing.

Expected impact

Minimal price movement expected.

Evidence & confidence

The transaction size is tiny relative to market cap; unlikely to move the stock.

Market effects

Sector

No significant effect on the biotech sector.

Regional

Limited to US biotech investors.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can precede larger moves if management signals confidence.

Key entities

  • company
    Tonix Pharmaceuticals Holding Corp.

    Biotech company listed on NASDAQ.

  • insider
    Richard Bagger

    Director of Tonix.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNXP insider trading history →

Related articles

AUG 24
$TNXPLow

Next-Generation Mpox Vaccine Shows Promise for Durable Protection and Future Outbreak Preparedness

Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin

infectioncontroltoday.com3 min
AUG 17
$TNXPMedAI 8/10

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.

fool.com6 min
AUG 10
$TNXPMedAI 8/10

Tonix Pharmaceuticals Holding Corp. (TNXP): Results of Operations and Financial Condition

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, no

SEC EDGAR 8-K7 min
AUG 10
$TNXPMedAI 8/10

Tonix's Fibromyalgia Treatment Reaches 136M Covered Lives

Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q2 2026 net product revenue of about $13.5M, up from $2.0M a year earlier, driven by TONMYA sales of about $11.0M and migraine products Zembrace SymTouch and Tosymra. TONMYA prescriptions rose to 12,592 and coverage expanded to ~136M lives. Cash was ~$176.2M at June 30, 2026; net loss was $40.6M.

stocktitan.net6 min